Search research articles
Contact Us
Filters
Showing results (1-10 of 91) with videos related to
Page
of 10
Sort By:
Current Opinion in Urology
|
December 1, 1999
Markers for recurrence of superficial bladder cancer: what is valid?
H G van der Poel
The Journal of Urology
|
September 17, 2004
Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells
H G van der Poel
European Urology
|
December 12, 2003
Smart drugs in prostate cancer
H G van der Poel
European Urology
|
November 1, 2005
Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer
H G van der Poel
Critical Reviews in Oncology/Hematology
|
September 2, 2006
Molecular markers in the diagnosis of prostate cancer
H G van der Poel
Current Opinion in Urology
|
August 9, 2001
Can biological markers replace cystoscopy? An update
H G van der Poel, F M Debruyne
European Journal of Morphology
|
March 1, 1994
Microwave-antigen retrieval for proliferation analysis (MIB-1) and quanticyt karyometry of bladder washings
H G Van der Poel, M E Boon
Urology
|
February 7, 2009
Role of extent of fascia preservation and erectile function after robot-assisted laparoscopic prostatectomy
H G van der Poel, W de Blok
European Urology
|
July 7, 1999
Clinical experience in Europe with uroselective alpha1-antagonists
F M Debruyne, H G Van der Poel
Journal of Surgical Oncology
|
March 25, 2008
Sequential treatment for recurrent localized prostate cancer
H G Van Der Poel, L Moonen, S Horenblas
Page
of 10
Search research articles
Search
Showing results (1-10 of 91) with videos related to
Sort By:
Page
of 10
Current Opinion in Urology
|
December 1, 1999
Markers for recurrence of superficial bladder cancer: what is valid?
H G van der Poel
The Journal of Urology
|
September 17, 2004
Mammalian target of rapamycin and 3-phosphatidylinositol 3-kinase pathway inhibition enhances growth inhibition of transforming growth factor-beta1 in prostate cancer cells
H G van der Poel
European Urology
|
December 12, 2003
Smart drugs in prostate cancer
H G van der Poel
European Urology
|
November 1, 2005
Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer
H G van der Poel
Critical Reviews in Oncology/Hematology
|
September 2, 2006
Molecular markers in the diagnosis of prostate cancer
H G van der Poel
Current Opinion in Urology
|
August 9, 2001
Can biological markers replace cystoscopy? An update
H G van der Poel, F M Debruyne
European Journal of Morphology
|
March 1, 1994
Microwave-antigen retrieval for proliferation analysis (MIB-1) and quanticyt karyometry of bladder washings
H G Van der Poel, M E Boon
Urology
|
February 7, 2009
Role of extent of fascia preservation and erectile function after robot-assisted laparoscopic prostatectomy
H G van der Poel, W de Blok
European Urology
|
July 7, 1999
Clinical experience in Europe with uroselective alpha1-antagonists
F M Debruyne, H G Van der Poel
Journal of Surgical Oncology
|
March 25, 2008
Sequential treatment for recurrent localized prostate cancer
H G Van Der Poel, L Moonen, S Horenblas
Page
of 10